Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2TSMD)

• Drug Name: 177Lu-labelled NeoBOMB1 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM2TSMD

Molecule-Related Drug Atlas

Drug(s) Targeting Gastrin-releasing peptide receptor (GRPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-7147	DMGDF2X	Irritable bowel syndrome	DD91.0	Phase 2	[3]
RC-3095	DMIG98L	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
177-Lu-NeoB	DM6JLNT	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
177Lu-AMBA	DMFG1YA	Breast cancer	2C60-2C65	Phase 1	[5]
BIM-26226	DM9F4LP	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]
kuwanon H	DMVQDNR	Discovery agent	N.A.	Investigative	[7]
bombesin	DMDFQ0Y	Discovery agent	N.A.	Investigative	[8]
PD 168368	DMFNQEA	Discovery agent	N.A.	Investigative	[9]
MK-5046	DMS7C6R	Discovery agent	N.A.	Investigative	[10]
bantag-1	DM4OT8M	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastrin-releasing peptide receptor (GRPR)	TTC1MVT	GRPR_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03724253) [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NeoFIND). U.S. National Institutes of Health.
• [2] 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
• [3] Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
• [4] Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8.
• [5] Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48.
• [6] Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86.
• [7] Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
• [8] Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
• [9] Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11.
• [10] Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.